NASDAQ Biotech Executive Sells Shares After Exercising $1.5 Million Stock Options

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biotech company, disclosed that its Chief Medical Officer and Head of R&D, Harold Bernstein, exercised 30,000 stock options on March 10 and immediately sold all 30,000 shares on the open market under a pre-authorized Rule 10b5-1 plan.

The shares traded at approximately $50–$51 each, generating roughly $1.51 million in gross proceeds and an intrinsic gain of about $1.2 million. Following the sale, Bernstein still holds around 300,000 Maze shares, with his remaining stake valued at approximately $15.13 million, according to the company’s filing.

On February 4, Maze entered into a senior secured credit facility of up to $200 million with Hercules Capital, drawing $40 million initially to repay existing bank debt and restructure its balance sheet. The company plans to use this financing, together with previously raised funds, to advance Phase 2 trials of its lead pipeline candidates—MZE829 for APOL1-mediated kidney disease and MZE782 for rare metabolic disorders.

Headquartered in South San Francisco, California, Maze Therapeutics went public on Nasdaq in 2025. The firm leverages human genetics data to discover and develop therapies for kidney and other rare diseases. Bernstein, who oversees the company’s R&D and clinical strategy, is identified in SEC filings as a key executive responsible for decision-making on its major development programs.